.Pharmacolibrary.Drugs.ATC.G.G04BE08 .Pharmacolibrary.Drugs.ATC.G.G04BE08| name: | Tadalafil | |
| ATC code: | G04BE08 | route: | oral |
| compartments: | 2 | |
| dosage: | 20 | mg |
| volume of distribution: | 63 | L |
| clearance: | 2.4 | L/h |
| other parameters in model implementation | ||
Tadalafil is a selective phosphodiesterase type 5 (PDE5) inhibitor used for the treatment of erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension. It is an orally administered drug, approved and widely used in clinical practice.
Pharmacokinetic parameters reported in healthy adult males after a single oral dose administration.
Trocóniz, IF, et al., & Forgue, ST (2007). Tadalafil population pharmacokinetics in patients with erectile dysfunction. European journal of clinical pharmacology 63(6) 583–590. DOI:10.1007/s00228-007-0297-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/17431603
Briganti, A, et al., & Montorsi, F (2005). Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction. Nature clinical practice. Urology 2(5) 239–247. DOI:10.1038/ncpuro0186 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16474835
Porst, H, et al., & Sharlip, I (2013). SOP conservative (medical and mechanical) treatment of erectile dysfunction. The journal of sexual medicine 10(1) 130–171. DOI:10.1111/jsm.12023 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23343170